Maynard Um
-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Lowered to $58 at Raymond James
-
-
-
-
-
-
-
Legend Biotech presents early solid tumor data for LB2102 at ASCO 2026
-
-
-
-
-
-
-
Raymond James on Legend Biotech Corp. (LEGN): 'the dataset suggests very strong efficacy with room for improvement on safety'
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Raritan's full manufacturing slot capacity approved"
-
-
-
-
-
-
-
TD Cowen Downgrades Legend Biotech Corp. (LEGN) to Hold
-
-
-
-
-
-
-
Legend Biotech reports 50-month survival data for CARVYKTI in myeloma
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
445,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

